You've been automatically redirected here from Humanzyme.com, which is now part of Proteintech Group. Click here to dismiss this alert.
Important Customer Notice Regarding Covid-19 Outbreak. Read more.

Kidney Cancer

Proteintech offers a wide range of markers and related antibodies for kidney cancer.

Proteintech offers a wide range of markers and related antibodies for kidney cancer.


There are different types of kidney cancer. Renal cell carcinoma (RCC) is the most common. RCC shows resistance to radiation or chemotherapy, thus surgery is the most promising treatment method. Renal cell carcinoma accounts for 2-3% of all cancers, with the highest incidence occurring in Western countries.

APOL1: It's new role in kidney disease
Alterations in ApolipoproteinL (ApoL1) functions lead to different lipid disorders. Several current studies show that the ApoL1 protein is involved in different kidney diseases.¹, ², ³, ⁴
IHC staining of paraffin-embedded human kidney tissue using APOL1 antibody (11486-2-AP) at a dilution of 1:50 (40x objective)
IHC staining of paraffin-embedded human kidney tissue using APOL1 antibody (11486-2-AP) at a dilution of 1:50 (40x objective).

Related antibodies

Antibody name Catalog number Type
APOL1 66124-1-IG Mouse Mono
APOL1 11486-2-AP Rabbit Poly
APOL1 KE00047 ELISA Kit
SIX2: Investigating kidney development

It has previously been shown that SIX2 is expressed in developing mesenchymal tissue including renal differentiation. SIX2 also significantly marks renal progenitor cells, and is therefore a powerfool tool to distinguish between the ureteric bud (UB) and the nephrogenic “cap” mesenchyme (CM).⁵

Immunofluorescence staining using SIX2 antibody (11562-1-AP) of mouse embryonic kidney rudiment dissected at E13.5 and cultured for 2 days by Dr. Aleksandra Rak-Raszewska.
Antibody name Catalog number Type
SIX2 11562-1-AP Rabbit Poly
CA9: A marker for diagnosis, prognosis, and treatment
Carbonic anhydrase 9 (CA9) is a transmembrane member of the carbonic anhydrase family. CA9 is a marker specific for renal cell carcinoma. It has been shown that CA9 is not expressed in healthy renal tissue but is expressed in most clear cell renal cell carcinomas.⁶, ⁷
Immunohistochemical staining of paraffin-embedded human renal cell carcinoma tissue using CA9 antibody (66243-1-IG) at a dilution of 1:400 (40x objective). Heat-mediated antigen retrieved with Tris-EDTA buffer (pH9)
Immunohistochemical staining of paraffin-embedded human renal cell carcinoma tissue using CA9 antibody (66243-1-IG) at a dilution of 1:400 (40x objective). Heat-mediated antigen retrieved with Tris-EDTA buffer (pH9).
Antibody name Catalog number Type
CA9 66243-1-IG Mouse Mono

Related antibodies

Antibody name Catalog number Type
CA2 16961-1-AP Rabbit poly
Calbindin 14479-1-AP Rabbit poly
GSTT1 15838-1-AP Rabbit poly
NKCC2 18970-1-AP Rabbit poly
PDK1 18262-1-AP Rabbit poly
Renin 14291-1-AP Rabbit poly
Synaptopodin 21064-1-AP Rabbit poly
VEGF 19003-1-AP Rabbit poly
Related: Protein ladders for your WB experiments
Prestained Protein Ladder (free samples available) Broad Range Prestained Protein Ladder
Molecular weight coverage: 10-180 kDa  Molecular weight coverage: 3-245 kDa  
Catalog no.: PL00001
Catalog no.: PL00002
prestained protein marker with 10 markers covering a wide range of molecular weights from 10 to 180 kDa broad range prestained protein marker with 13 markers covering a wide range of molecular weights from 3 to 245 kDa
Resolution of the prestained protein ladder in a 10-20% Tris-glycine gel (SDS-PAGE). The image shows the migration pattern in the gel and after transfer to a PVDF membrane. Resolution of the prestained protein ladder in a 4-12% Bis-Tris gel (SDS-PAGE). The image shows the migration pattern in the gel and after transfer to a PVDF membrane.

References

¹ Tzur S, et al. Human Genetics, 2010; 128: 345–50.

² Behar D, et al. Am J Kidney Dis, 2006; 47: 88–94.

³ Lan X, et al. Experimental and Molecular Pathology 2015; 98: 491–501.

⁴ Hu C, et al. FEBS Lett. 2012; 586: 947–55.

⁵ Short K, et al. Developmental Cell, 2014; 29: 188–202.

⁶ Tostain J, et al. Eur J Cancer. 2010; 46: 3141–8

⁷ Soyupak B, et al. Urol Int. 2005; 74: 68–73.

Featured Products

Posted:
1 April, 2020

Share: